November 16, 2016
Across the United States, the high cost of hepatitis C (HCV) drugs means that patients often struggle to access life-saving treatment. State-level Medicaid programs are legally obligated to provide these drugs, but many programs find ways to deny treatment. The three more common tactics employed are liver damage (fibrosis) restrictions, prescriber restrictions and sobriety restrictions.
While restrictions vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to preliminary data presented at the Liver Meeting 2016, by Robert Greenwald, director, Center for Health Law and Policy Innovation at Harvard Law School, and Ryan Clary, executive director of the National Viral Hepatitis Roundtable. Greenwald presented the 2016 data as an update to his 2014 survey of state Medicaid policies.
Credit: zimmytws for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|The Best HIV Cure Will Be Built With Us, Not Just for Us|
|The Power of Positive Thinking Could Help Lower Viral Load|
|The Curious Case of M184V, Part 1|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|WHO Adds Dolutegravir and PrEP to Updated Essential Medicine List|